Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$95.2 million.

  • Compass Therapeutics' Cash from Investing Activities fell 42792.06% to -$95.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.6 million, marking a year-over-year decrease of 29768.27%. This contributed to the annual value of $46.8 million for FY2024, which is 7345.45% up from last year.
  • As of Q3 2025, Compass Therapeutics' Cash from Investing Activities stood at -$95.2 million, which was down 42792.06% from -$6.4 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Cash from Investing Activities high stood at $29.0 million for Q3 2024, and its period low was -$95.2 million during Q3 2025.
  • In the last 3 years, Compass Therapeutics' Cash from Investing Activities had a median value of $6.3 million in 2023 and averaged -$1.5 million.
  • Per our database at Business Quant, Compass Therapeutics' Cash from Investing Activities surged by 107196.4% in 2024 and then plummeted by 42792.06% in 2025.
  • Compass Therapeutics' Cash from Investing Activities (Quarter) stood at $6.3 million in 2023, then skyrocketed by 143.43% to $15.4 million in 2024, then tumbled by 719.1% to -$95.2 million in 2025.
  • Its Cash from Investing Activities was -$95.2 million in Q3 2025, compared to -$6.4 million in Q2 2025 and $11.6 million in Q1 2025.